PPT-Critical Risk Assessment and Management Practices in Pharmaceutical Industry Abida Zameer

Abida Zameer Harrisburg University GRAD 699 PGMT Agenda Introduction and Problem Statement Methodology Results Discussion Conclusions Special Characterstics of the pharmaceutical industry . Module 2 – Disaster Resilience Standard. June 2012. Hazard and Threat Assessment. 3.2.1 – The organization has identified the hazards and threats it faces and assessed their impacts on the organization’s operations. 2. This presentation is designed to be tailored. Review the slides and select the ones that are appropriate for your audience and time allotted – hide the rest.. Hidden Slide. 3. Were the following mishaps . Conference . Report – part 1. Total number of selected abstracts – 19. Total Number Presented – 6. Session 1: . Enironmental. Statistics and Decision Support Systems . Presentations covered the following topics . March 27th 2014, University of Zurich . Fabienne Heimgartner, Interpharma. What. . it. . needs. . for. . one. . drug. CHF . investment. working. . hours. . experiments. scientists. drug. 1 000 000 000. Quality . and . Environmental Requirements. Expectations from European industry . regarding . collaboration on drug quality and environment. A Global industry acts with global standards. 2. Excellence Builds on Continual Improvement. of . Pharmaceutical Mixtures:. -. empirical . knowledge, gaps and regulatory options. Thomas Backhaus . University of Gothenburg . thomas.backhaus@gu.se. [T]here are . known . knowns. ; there are things we know that we know. Best Practices:. It all began with the Roadmap…. Roadmap Goals. Become Industry Action. Best Practices Are…. techniques or methods. that, through . experience and research. , . have proven they will reliably lead to a . Patricia C. Kienle, RPh, MPA, FASHP. Director, Accreditation and Medication Safety. Cardinal Health Innovative Delivery Solutions. Disclaimer. Patricia Kienle is an employee of Cardinal Health. She is a member of the USP Compounding Expert Committee, but this presentation is not endorsed by or affiliated with USP. Human Capital Outlook Implications for Skills Development in the Pharmaceutical Sector. Johannesburg. May 27 2015. Disclaimer . Any views or opinions expressed herein are solely those of the author and do not necessarily represent those of any company. Curtis Smith. November 30, . 2016. Big Data Panel Discussion. Big . Data and the Pharmaceutical Industry. 2. There has been substantial change to the . Pharmaceutical data . environment over the last 5 years. . March 27th 2014, University of Zurich . Fabienne Heimgartner, Interpharma. What. . it. . needs. . for. . one. . drug. CHF . investment. working. . hours. . experiments. scientists. drug. 1 000 000 000. Curtis Smith. November 30, . 2016. Big Data Panel Discussion. Big . Data and the Pharmaceutical Industry. 2. There has been substantial change to the . Pharmaceutical data . environment over the last 5 years. . . . *. . Date: . April. . 28, 2017 . *. . . Proposals. from the . European. . Pharmaceutical. Industry for . PiE. (Pharmaceuticals in the Environment. ). 201. 7. . China/EU Pharmaceutical Industry Forum, in . This template can be used to create a PowerPoint for use in a risk assessment workshop. Slides 3 and 17-21 contain standard information regarding the environments (slide 3) and the risk assessment process (slides 17-21).